Area of research
Hematology · Genetics
Research interest
Research interests include Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Acute Myeloid Leukemia Research, and Eosinophilic Disorders and Syndromes.
How I individualize frontline treatment for chronic-phase CML.
Response rate and survival of patients with chronic-phase chronic myeloid leukemia on second-line treatment in Tanzania
Resistance to Allosteric Inhibitors
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
<i>BCR</i>::<i>ABL1</i> kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.
The promise of allosteric kinase inhibition.
Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of <scp>DASFREE</scp>
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia
Ponatinib after failure of <scp>second‐generation</scp> tyrosine kinase inhibitor in resistant <scp>chronic‐phase</scp> chronic myeloid leukemia
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia
Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
Precision medicine to prevent glaucoma-related blindness
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial